

1 **Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size**

2

3 Maggie C. DUNCAN^{1,2}, F. Harrison OMONDI^{1,2}, Natalie N. KINLOCH^{1,2}, Hope R.
4 LAPOINTE¹, Sarah SPECKMAIER¹, Nadia MORAN-GARCIA¹, Tanya LAWSON³, Mari
5 L. DeMarco^{4,5}, Janet SIMONS^{4,5}, Daniel T. HOLMES^{4,5}, Christopher F. LOWE^{3,4,5}, Nic
6 BACANI¹, Paul SEREDA¹, Rolando BARRIOS^{1,6}, Marianne HARRIS^{1,7}, Marc G.
7 ROMNEY^{3,4,5}, Julio S.G. MONTANER^{1,8}, Chanson J. BRUMME^{1,8}, Mark A.
8 BROCKMAN^{1,2,9}, Zabrina L. BRUMME^{1,2}.

9

10

11 ¹ British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada

12 ² Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

13 ³ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada

14 ⁴ Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver,
15 Canada

16 ⁵ Department of Pathology and Laboratory Medicine, University of British Columbia,
17 Vancouver, Canada

18 ⁶ School of Population and Public Health, University of British Columbia, Vancouver,
19 Canada

20 ⁷ Department of Family Practice, Faculty of Medicine, University of British Columbia,
21 Vancouver, Canada

22 ⁸ Department of Medicine, University of British Columbia, Vancouver, Canada;

23 ⁹ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby,
24 Canada

25 Short Title: COVID-19 mRNA vaccines and the HIV reservoir

26 Word Count: Abstract: 250/250; Text: 3491/3500

27

28

29

30 Corresponding Author:

31 Zabrina L. Brumme, Ph.D.,

32 Faculty of Health Sciences, Simon Fraser University,

33 8888 University Drive, Burnaby, BC, Canada, V5A 1S6;

34 Tel: 778 782-8872; Fax: 778-782-5927;

35 email: zbrumme@sfu.ca; zbrumme@bccfe.ca

36

37

38 **Abstract:**

39 **Objective:** The immunogenic nature of COVID-19 mRNA vaccines led to some initial
40 concern that these could stimulate the HIV reservoir. We analyzed changes in plasma HIV
41 loads (pVL) and reservoir size following COVID-19 mRNA vaccination in 62 people with
42 HIV (PWH) receiving antiretroviral therapy (ART), and analyzed province-wide trends in
43 pVL before and after the mass vaccination campaign.

44

45 **Design:** Longitudinal observational cohort and province-wide analysis.

46

47 **Methods:** 62 participants were sampled pre-vaccination, and one month after their first and
48 second COVID-19 immunizations. Vaccine-induced anti-SARS-CoV-2-Spike antibodies in
49 serum were measured using the Roche Elecsys Anti-S assay. HIV reservoirs were
50 quantified using the Intact Proviral DNA Assay; pVL were measured using the cobas 6800
51 (LLOQ:20 copies/mL). The province-wide analysis included all 290,401 pVL performed in
52 British Columbia, Canada between 2012-2022.

53

54 **Results:** Pre-vaccination, the median intact reservoir size was 77 (IQR:20-204) HIV
55 copies/million CD4+ T-cells, compared to 74 (IQR:27-212) and 65 (IQR:22-174) post-first
56 and -second dose, respectively (all comparisons $p>0.07$). Pre-vaccination, 82% of
57 participants had $pVL<20$ copies/mL (max:110 copies/mL), compared to 79% post-first
58 dose (max:183 copies/mL) and 85% post-second dose (max:79 copies/mL) ($p>0.4$). The
59 magnitude of the vaccine-elicited anti-SARS-CoV-2-Spike antibody response did not
60 correlate with changes in reservoir size nor detectable pVL frequency ($p>0.6$). We found no

61 evidence linking the COVID-19 mass vaccination campaign to population-level increases
62 in detectable pVL frequency among all PWH in the province, nor among those who
63 maintained pVL suppression on ART.

64

65 **Conclusion:** We found no evidence that COVID-19 mRNA vaccines induced changes in
66 HIV reservoir size nor plasma viremia.

67

68 **Keywords:** COVID-19 vaccine, mRNA, HIV, reservoir size, IPDA, plasma viral load

69 **Introduction**

70 The mass rollout of safe and effective SARS-CoV-2 mRNA vaccines was critical in
71 combatting the COVID-19 pandemic. As people with HIV (PWH) are at a higher risk of
72 severe COVID-19 outcomes [1–3], it was particularly important for this group to be
73 vaccinated, and a large body of evidence now reassuringly confirms that PWH receiving
74 suppressive antiretroviral therapy (ART) generally mount robust immune responses to
75 COVID-19 vaccination [4–12]. Initially however, COVID-19 vaccine confidence was
76 typically lower among PWH compared to the general population [13,14], with possible
77 effects of vaccination on viral rebound cited among the concerns [15,16]. Such concerns
78 are not entirely unfounded, as some vaccines, including those against influenza, Hepatitis B,
79 and pneumococcus can induce HIV transcription, leading to transient increases in plasma
80 HIV RNA levels [17–21].

81 The immunogenic nature of mRNA vaccines, which elicit strong humoral and cell-
82 mediated immune responses by harnessing innate detectors of single-stranded viral RNA
83 [22,23], led to some initial concerns that these might induce HIV expression, and possibly
84 viral release, from the reservoir [24]. This could theoretically occur via direct stimulation of
85 reservoir cells that recognize the vaccine antigen, or through a generalized inflammatory
86 response with cytokine production that could transiently promote HIV gene expression.
87 Indeed, reports of increased HIV viremia in individuals receiving ART following COVID-
88 19 mRNA vaccination have emerged [25–27], though other studies have observed no such
89 effects [28–30].

90 Existing studies however have been relatively modestly sized. A recent analysis of
91 35 PWH, which included 15 participants from the present cohort, reported that the

92 frequency of Nef-specific CD8+ T cells transiently increased after the initial COVID-19
93 mRNA vaccine dose, consistent with immune sensing of reactivated reservoir cells, but
94 plasma viremia was not investigated and no significant changes in reservoir size were
95 observed in the subset of 13 participants analyzed for this outcome [31]. Another analysis
96 of 25 PWH reported no significant changes in reservoir size post-COVID-19 vaccination
97 [29]. A recent analysis of 68 PWH reported a gradual yet not statistically significant
98 increase in pVL after the second vaccine dose with no obvious effects on reservoir size, but
99 nearly half of participants received the viral vectored ChAdOx1 vaccine (which may be less
100 likely to modulate the reservoir), and pVL and reservoir data were available for fewer than
101 two-thirds of the cohort [27]. To our knowledge, no studies have investigated the effects of
102 COVID-19 mRNA vaccination on the reservoir in an observational cohort while also
103 analyzing population-level trends in pVL test results in a large geographic region following
104 mass COVID-19 vaccination.

105 Here, we analyzed changes in pVL and reservoir size following the first and second
106 COVID-19 mRNA vaccine doses in 62 PWH receiving ART. Using a longitudinal dataset
107 that captured all PWH in British Columbia (BC), Canada, we also investigated whether the
108 frequency of detectable HIV RNA test results increased at the population level following
109 the mass administration of first, second and booster COVID-19 vaccine doses in the
110 province.

111 **Methods**

112 **Cohort and specimen collection**

113 Our cohort of PWH on ART, established at the outset of the mass COVID-19
114 vaccination campaign in BC, has been described previously [6]. The present analysis
115 includes all PWH who provided a pre-vaccination sample and who received two mRNA
116 vaccine doses (either BNT162b2 or mRNA-1273). Serum, plasma and peripheral blood
117 mononuclear cells (PBMC; isolated by density gradient separation and cryopreserved
118 at -150°C until analysis) were collected pre-vaccination, and again one month after the first
119 and second vaccine doses.

120

121 **Ethics Approval**

122 The cohort study was approved by the University of British Columbia/Providence
123 Health Care and Simon Fraser University Research Ethics Boards. All participants provided
124 written informed consent. The BC Centre for Excellence in HIV/AIDS (BC-CfE) Drug
125 Treatment Program (DTP), the source of the province-wide pVL dataset, is a provincially-
126 funded clinical registry mandated to: i) deliver health care to individuals living with HIV
127 and related diseases, or at risk of HIV infection, ii) implement and support public health
128 initiatives to curb HIV/AIDS, iii) monitor and evaluate these health care programs, and iv)
129 support related knowledge translation and educational programs. As a result, the
130 requirement for REB review of the province-wide pVL analysis was waived by the
131 Providence Health Care/University of British Columbia REB.

132

133 **Anti-SARS-CoV-2 antibody assays**

134 Total binding antibodies against SARS-CoV-2 nucleocapsid (N) and spike receptor
135 binding domain (RBD) in serum were measured using the Roche Elecsys Anti-SARS-CoV-
136 2 and Anti-SARS-CoV-2 S assays, respectively. Both are electro-chemiluminescence
137 sandwich immunoassays. The presence of anti-N antibodies identified participants with
138 prior SARS-CoV-2 infection. The S assay reports results in arbitrary units/mL (U/mL)
139 calibrated against an external standard, where the measurement range is from 0.4-25,000
140 U/mL.

141

142 **Plasma HIV RNA quantification**

143 Plasma HIV RNA levels were quantified using the cobas Ampliprep/Taqman HIV-1
144 Test v2.0 (during the period March 7, 2012 – June 4, 2018) or the cobas HIV-1 Test on a
145 cobas 6800 (from June 5, 2018 – present; Roche Diagnostics). The lower limit of
146 quantification (LLOQ) of this test is 20 HIV RNA copies/mL. This threshold defined
147 undetectable viremia, unless otherwise indicated.

148

149 **HIV Reservoir Quantification**

150 CD4⁺ T-cells were isolated from PBMCs via negative selection using the EasySep
151 Human CD4⁺ T-cell Enrichment Kit (STEMCELL Technologies). Median CD4⁺ T-cell
152 purity, assessed flow cytometrically post-isolation, was 97%. Genomic DNA was extracted
153 from a median of 2.9 (Interquartile Range [IQR] 2.2-3.8) million CD4⁺ T-cells using the
154 QIAamp DNA Mini Kit (QIAGEN). HIV reservoir quantification was performed using the

155 Intact Proviral DNA Assay (IPDA) [32] as described previously [33]. Briefly, this droplet
156 digital PCR assay distinguishes genomically-intact proviruses from the vast background of
157 defective ones by simultaneously targeting two HIV regions, the Packaging Signal (Ψ) near
158 the 5' end of the viral genome and the Rev Responsive Element (RRE) within Envelope
159 (*env*), that together strongly predict genomic intactness. An unlabeled competitive RRE
160 probe specific for hypermutated proviruses ensures that these are not counted as intact.
161 Occasionally, the published IPDA primers/probes fail to detect a participant's proviral pool
162 due to sequence polymorphism [33], which occurred in 14 (23%) of participants. For these,
163 we employed a secondary *env* reaction [33] or custom autologous primers/probes. The
164 assay also quantifies human genomic DNA in an independent parallel reaction, using
165 primer/probe sets in the human RPP30 gene that are spaced the same distance apart as the
166 HIV target regions. This spacing also allows each sample's data to be corrected for the
167 DNA shearing that occurs during extraction (by measuring the frequency whereby the
168 RPP30 targets are decoupled). The assay reports the number of intact HIV genomes (those
169 positive for both Ψ and RRE), as well as the overall number of proviral DNA copies (those
170 positive for at least one target), per million CD4+ T-cells.

171 A median of 290,000 (IQR 255,000-325,000) cells were assayed per participant
172 across four replicate wells, which were merged to generate the final reservoir measurement.
173 Genomic DNA from J-Lat 9.2 cells, which harbor a single integrated copy of replication-
174 incompetent HIV per cell, was used as a positive control, while genomic DNA from donors
175 without HIV, and water, were used as negative controls. Droplets were read using the
176 QX200 Droplet Reader (BioRad) and analysed using QuantaSoft (BioRad, version 1.7.4).

177 Wells containing fewer than 10,000 droplets were excluded from analysis. The median
178 DNA shearing was 0.38 (IQR 0.35-0.39), well within the acceptable range [32].

179

180 **Temporal analysis of HIV plasma viral load test results in British Columbia**

181 The BC Centre for Excellence in HIV/AIDS (BC-CfE) provides care and treatment
182 for all PWH in the province. The BC-CfE's Drug Treatment Program (DTP) database
183 captures all HIV plasma viral load (pVL) tests and ART information for all PWH in BC.
184 We analyzed all 290,401 pVL tests performed between January 2012 and December 2022
185 to investigate whether the frequency of detectable pVL test results increased following each
186 "wave" of mass COVID-19 vaccination in the province. Though the LLOQ of the pVL
187 assay is 20 copies/mL, the results are clinically reported (and thus stored in the DTP
188 database) with a LLOQ of 40 copies/mL. COVID-19 vaccine distribution data for BC up to
189 December 2022 (where 97% of vaccines administered were mRNA) [34] were retrieved
190 from the Public Health Agency of Canada and COVID-19 Vaccine Tracker [34–36].

191

192 **Statistical Analysis**

193 Comparisons of continuous variables between groups were performed using the
194 Mann-Whitney U-test (for unpaired data) or Wilcoxon test (for paired data). Correlations
195 between continuous variables were performed using Spearman's correlation. Frequency
196 comparisons were performed using the χ^2 test. Where appropriate, multiple comparisons
197 were addressed using a false-discovery rate (q-value) approach [37]. All statistical tests
198 were performed in using R (version 4.3.1).

199 **Results**

200 **Participant characteristics**

201 The 62 PWH participants in the observational cohort study were a median 43 years
202 old and 55 (89%) were male. Participants had been receiving ART for a median of 6 years,
203 with 74% on integrase inhibitor-based ART at enrolment (**Table 1**). The most recent CD4+
204 T-cell count, measured a median of 40 (IQR 15-159) days before enrolment, was 725 (IQR
205 475-915; range 130-1800) cells/mm³. The estimated nadir CD4+ T-cell count, recorded a
206 median of 5.6 (IQR 2.8-13) years before enrolment, was 305 (IQR 160-499; range <9-970)
207 cells/mm³. At the baseline (pre-vaccination) visit, 51 (82%) of participants had pVL below
208 the LLOQ of 20 copies HIV RNA/mL (the highest pVL observed at baseline was 110
209 copies/mL). Overall, 69% of participants received two doses of the BNT162b2 COVID-19
210 mRNA vaccine, 26% received two doses of mRNA-1273, and 5% received a mixed mRNA
211 regimen. Of note, the interval between first and second COVID-19 doses was extended to
212 up to 112 days in Canada due to initially limited vaccine supplies in the country [38]. The
213 vast majority (57/62; 92%) of participants remained COVID-19 naive throughout follow-up,
214 four experienced COVID-19 before vaccination, and one acquired COVID-19 between the
215 first and second vaccine doses.

216

217 **No evidence that COVID-19 mRNA vaccination induces detectable viremia**

218 HIV pVL testing was performed at the baseline visit, which occurred a median of
219 12 (IQR 3-26) days prior to vaccination, one month (a median of 31 [IQR 29-33] days)
220 after the first vaccine dose, and again one month (a median of 30 [IQR 29-30] days) after

221 the second vaccine dose (**Fig. 1**). At baseline, 82% (51/62) of participants had a pVL <20
222 copies/mL, where the highest observed value was 110 copies/mL. One month after the first
223 vaccine dose, 79% (49/62) of participants had pVL <20 copies/mL (highest value 183
224 copies/mL), a difference that was not statistically significant from baseline (Wilcoxon
225 paired test; $p=0.46$). One month after the second dose, three participants had temporarily
226 discontinued ART or missed the visit, leaving 59 participants for analysis. Of these, 85%
227 (50/59) had pVL <20 copies/mL (highest value 79 copies/mL), which was not significantly
228 different compared to baseline ($p=0.81$), nor one month post-first dose ($p=0.88$). Using a
229 pVL <50 copies/mL threshold produced consistent results: at baseline, 94% (58/62) of
230 participants had a pVL <50 copies/mL, compared to 92% (57/62) one month after the first
231 vaccine dose, and 93% (55/59) after the second (Chi-squared $p=0.93$). At no point did any
232 participant experience virologic failure (defined as >200 copies/mL [39,40]). Results also
233 remained consistent after excluding visits from participants who had experienced
234 COVID-19 (all $p>0.59$; not shown). Stratification of the data by sex, COVID-19 vaccine
235 regimen, and ART regimen similarly produced no statistically significant differences in
236 pVL between baseline and post-vaccination visits for any subgroup (all $p>0.08$; $q>0.78$; not
237 shown).

238

239 **No changes in HIV reservoir size after COVID-19 mRNA vaccination**

240 To determine whether COVID-19 mRNA vaccination induced changes in HIV
241 reservoir size (defined as genome-intact proviral load) or total HIV DNA load, we
242 quantified the number of intact, defective and total proviral copies per million CD4+

243 T-cells (**Fig. 2**) [32]. At baseline, the median number of intact HIV copies per million
244 CD4+ T-cells was 77 (IQR 20-204). One month following the first vaccine dose it was 74
245 (IQR 27-212), a difference that was not statistically significant (Wilcoxon paired test,
246 $p=0.64$) (**Fig. 2a**). One month following the second vaccine dose, the median intact
247 reservoir size was 65 (IQR 22-174), which was not significantly different from baseline
248 ($p=0.32$), nor one month post-first dose ($p=0.07$) (**Fig. 2a**). Likewise, 5'-defective,
249 3'-defective, and total proviral burdens did not change significantly between baseline and
250 either post-vaccine visit (**Fig. 2a-2d**; all $p>0.08$). These results remained consistent after
251 excluding data from participants who experienced COVID-19 (all $p>0.07$; not shown).
252 Stratification of the data by sex, vaccine, and ART regimen similarly produced no
253 statistically significant differences in intact reservoir size, nor in the total, 5'-defective nor
254 3'-defective proviral burdens for any subgroup, after adjusting for multiple comparisons
255 (all $q>0.24$; not shown).

256

257 **No evidence that the magnitude of the COVID-19-vaccine-induced immune response**
258 **increases the likelihood of HIV reservoir perturbation**

259 Based on the observation that PWH on ART who mounted strong responses to
260 influenza vaccination were more likely to show transient increases in HIV pVL [20], we
261 investigated whether the magnitude of the COVID-19-vaccine-induced immune response
262 increased the likelihood of HIV reservoir perturbation. We found no evidence to support
263 this: one month following the first vaccine dose, anti-SARS-CoV-2-Spike serum antibody
264 concentrations were a median of 51.4 (19.4-130.6 U/mL) in participants who maintained

265 pVL <20 copies/mL versus a median of 36.6 (16.4-80.7 U/mL) among participants with a
266 pVL >20 HIV copies/mL, a difference that was not statistically significant (Mann-Whitney
267 $p = 0.73$; **Fig. 3a**). Similarly, one month after the second vaccine dose, anti-SARS-CoV-2-
268 Spike serum antibody concentrations were median of 8970 (5019-13544 U/mL) and 7205
269 (4163-11638 U/mL) respectively in participants with pVL <20 versus >20 copies/mL, a
270 difference that was not statistically significant ($p=0.84$; **Fig. 3b**).

271 Likewise, the magnitude of anti-SARS-CoV-2-Spike serum antibody levels one
272 month after the first vaccine dose did not correlate with the fold-change in reservoir size
273 from baseline (Spearman $\rho=0.05$, $p=0.69$; Fig. 3c), nor did the magnitude of
274 anti-SARS-CoV-2-Spike serum antibody levels one month after the second vaccine dose
275 correlate with the fold-change in reservoir size from the prior visit (Spearman $\rho=0.03$,
276 $p=0.82$; Fig. 3d). Both the pVL and reservoir size results remained consistent after
277 excluding the participants with prior COVID-19 (all $p>0.51$; not shown). Overall, the
278 results from our observational cohort do not provide any evidence that COVID-19 mRNA
279 vaccines modulated the HIV reservoir nor induced plasma viremia.

280

281 **Province-wide analysis of trends in HIV plasma viral loads before and after mass** 282 **COVID-19 vaccination**

283 We next investigated whether BC's mass COVID-19 vaccination campaign was
284 associated with an increase in the frequency of detectable pVL test results (defined here as
285 pVL >40 copies HIV RNA/mL; see methods) at the population level. We began by
286 analyzing all 290,401 pVL tests performed in BC since 2012. These represented all pVL

287 tests performed as part of routine clinical care of all PWH in BC, regardless of the
288 individual's ART status at the time of testing (the number of PWH undergoing pVL testing
289 in a given year ranged from 7112-8095 during this period) (**Fig. 4a**). Between 2012 and
290 approximately 2016, the percentage of detectable pVL test results declined from nearly
291 29% to an average of 16% as a result of a province-wide implementation of widespread
292 HIV testing and immediate initiation of free-of-charge ART that began in 2013 [41]. Since
293 2016, the overall percentage of detectable pVL has remained relatively stable, though there
294 was a slight uptick in the proportion of detectable pVL tests during 2020 because care
295 providers were asked to reduce the frequency of routine pVL testing for PWH with long-
296 term viremia suppression, to preserve lab capacity for COVID-19 diagnostic testing (which
297 was also performed on the cobas 6800 in BC).

298 COVID-19 vaccines were first made available to priority populations in BC, namely
299 frontline health workers, long-term care residents and individuals with select clinical
300 conditions (which did not include HIV infection) starting in late December 2020. The age-
301 based mass immunization campaign began in April 2021, which is when the majority of
302 PWH became eligible for COVID-19 vaccination. Peak administration of first doses
303 occurred from approximately May through September 2021, with second doses largely
304 administered from February to March 2022 (**Fig. 4a**). By April 10th, 2022, 89% of all adult
305 British Columbians had received at least two COVID-19 vaccine doses [35]. Notably, we
306 observed no obvious evidence of population-level increases in detectable pVL during or
307 immediately following the peak vaccine administration periods in the province (**Fig. 4a**).

308 As transient, vaccine-induced viremia may only be observable in PWH on
309 suppressive ART, we next restricted the province-wide analysis to PWH receiving

310 uninterrupted ART, defined as those with continuous monthly prescription refill records in
311 a given year. We then determined the annual percentage of PWH receiving uninterrupted
312 ART who experienced at least one detectable pVL that year. We began the analysis in 2019,
313 the year before the COVID-19 pandemic was declared (and the first full year that the cobas
314 6800 HIV Test was implemented) (**Fig. 4b**). Between 4903 and 5975 PWH were included
315 in each year's analysis. In 2019, 18.7% of PWH receiving uninterrupted ART experienced
316 at least one detectable pVL. In 2020, the percentage was 16.8%, though this reduction may
317 be attributable to the temporary reduction in pVL testing that year. By 2021, pVL testing
318 returned to pre-pandemic levels and >9 million COVID-19 vaccine doses were
319 administered provincewide in that year. Nevertheless, the percentage of PWH receiving
320 uninterrupted ART who experienced at least one detectable pVL measurement was 18.5%,
321 which was essentially identical to that observed in 2019 prior to the pandemic. The
322 percentage for 2022 was also 18.5%. Taken together, these results reveal no evidence
323 linking the provincial COVID-19 vaccination campaign to increases in detectable pVL at
324 the population level in BC.

325 **Discussion**

326 The mass rollout of COVID-19 mRNA vaccines provided an opportunity to study
327 the potential stimulatory effects of this new vaccine modality on the HIV reservoir. Though
328 a number of studies have now investigated this topic [27–29,31], their results have not been
329 entirely conclusive. While one study found evidence of a gradual, though not statistically
330 significant increase in the rate of detectable viremia peaking 4 weeks after the second
331 vaccine dose [27], two others reported no changes in viremia following two-dose
332 vaccination [28,30]. Two studies reported reduced frequencies of detectable viremia after
333 three-dose vaccination [28,29], though in one study this was likely attributable to increased
334 time on ART, which was initiated around the study outset for many participants [28]. Ours
335 is the first study to our knowledge to combine cohort- and population-level analyses of
336 pVL trends during a mass COVID-19 mRNA vaccination campaign.

337 Overall, neither the cohort nor population-level analyses identified evidence that
338 COVID-19 mRNA vaccination promotes viral release from the reservoir to detectable
339 levels in plasma. One month after the first and second vaccine doses, the proportion of
340 participants with detectable pVL remained statistically unchanged from baseline, with no
341 participant experiencing virologic failure (defined as pVL>200 copies/mL [39,40]).
342 Moreover, there was no evidence that the magnitude of the anti-SARS-CoV-2-Spike
343 antibody response influenced the likelihood of experiencing plasma viremia post-
344 vaccination. Our province-wide analysis similarly found that the frequency of detectable
345 pVL test results remained stable at the population level following the mass administration
346 of first, second and booster COVID-19 vaccine doses in BC. This remained the case

347 whether we considered the overall PWH population, or the subset receiving uninterrupted
348 ART.

349 Our cohort-based analysis also found no evidence that COVID-19 mRNA
350 vaccination induced changes in HIV reservoir size, nor in total, 5'-defective, or 3'-defective
351 proviral loads. This is consistent with findings from of three studies that assessed smaller
352 numbers of participants for this outcome using similar approaches [27,29,31].

353 Our study has some limitations and caveats. We sampled our cohort one month
354 following each COVID-19 vaccine dose because our primary objective was to evaluate
355 vaccine immune responses in PWH, as previously reported [6]. This timing however would
356 have missed rapid viremia events that had resolved by this time (indeed, such rapid viremia
357 events have been reported for influenza vaccination [20]). That said, in reports describing
358 viremia following COVID-19 vaccination, including the single case study, viremia was
359 detectable one month post-vaccination [25,27]. Another limitation is that our province-wide
360 evaluation represents an ecological analysis that correlated population-level pVL and
361 vaccination data, because COVID-19 vaccination dates of individual British Columbians
362 were not available to us. Thus, even though this analysis captured all HIV pVL tests
363 performed in BC during the period of interest, the variable timing of these tests with respect
364 to the individual's vaccination date would not have allowed us to capture all viremia events
365 that may have occurred. Finally, though neither our cohort nor population-level analyses
366 support frequent nor widespread effects of COVID-19 vaccination on the HIV reservoir, we
367 cannot rule out that such events may occur uncommonly, through mechanisms that remain
368 incompletely understood.

369 In conclusion, we found no evidence that COVID-19 mRNA vaccines induced
370 changes in HIV reservoir size nor plasma viremia in PWH receiving suppressive ART.
371 Taken together with similar findings from other studies [27–29,31], we conclude that there
372 is now a strong body of evidence indicating COVID-19 immunization is safe and effective
373 in PWH [4–12]. This should provide additional reassurance to PWH and their care
374 providers regarding the safety of COVID-19 mRNA vaccines.
375

376 **Acknowledgements:**

377 MCD and ZLB conceived and designed the study. MAB and ZLB obtained funding. HRL,
378 MH, MAB and ZLB established the cohort. MCD, FHO, NNK, SS and NM-G processed
379 specimens and/or collected IPDA data. MCD analyzed data and made figures. TL, CFL
380 and MGR performed the plasma viral load testing. MLD, JS, DTH and MGR performed the
381 COVID-19 serologic testing. NB, PS and CJB performed the province-wide viral load
382 analysis. JSGM and RB provided data access. MCD wrote the first draft of the paper, with
383 all authors contributing edits.

384

385 We are grateful to the study participants, without whom this research would not be possible.

386

387 This work was supported in part by the Canadian Institutes for Health Research (CIHR)
388 through a project grant (PJT-159625 to ZLB) and a team grant (HB1-164063 to ZLB and
389 MAB). This work was also supported in part by the National Institutes of Health (NIH)
390 through the Martin Delaney "REACH" Collaboratory (NIH grant 1-UM1AI164565-01 to
391 ZLB and MAB), which is supported by the following NIH cofounding institutes: NIMH,
392 NIDA, NINDS, NIDDK, NHLBI and NIAID. MCD was supported by a CIHR CGS-M
393 award. NNK was supported by a CIHR Vanier Canada Graduate Scholarship. MLD and
394 ZLB were supported by Scholar Awards from Michael Smith Health Research BC. The
395 content is solely the responsibility of the authors and does not necessarily represent the
396 official views of the National Institutes of Health or other funders.

397

398 **References**

399

400 1 Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, *et al.* **Outcomes of**
401 **Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People**
402 **With Human Immunodeficiency Virus (HIV) in the ISARIC World Health**
403 **Organization (WHO) Clinical Characterization Protocol (UK): A Prospective**
404 **Observational Study.** *Clin Infect Dis* 2020; **73**:e2095–e2106.

405 2 Tesoriero JM, Swain C-AE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, *et al.*
406 **COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV**
407 **Infection in New York State.** *JAMA Netw Open* 2021; **4**:e2037069.

408 3 Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, *et al.* **HIV**
409 **infection and COVID-19 death: a population-based cohort analysis of UK primary**
410 **care data and linked national death registrations within the OpenSAFELY**
411 **platform.** *Lancet HIV* 2021; **8**:e24–e32.

412 4 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, *et al.* **Safety**
413 **and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:**
414 **an interim analysis of four randomised controlled trials in Brazil, South Africa,**
415 **and the UK.** *Lancet* 2021; **397**:99–111.

416 5 Ruddy JA, Boyarsky BJ, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, *et al.*
417 **Safety and antibody response to two-dose SARS-CoV-2 messenger RNA**
418 **vaccination in persons with HIV.** *AIDS* 2021; **35**:2399–2401.

419 6 Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, *et al.*
420 **Humoral immune responses to COVID-19 vaccination in people living with HIV**
421 **receiving suppressive antiretroviral therapy.** *npj Vaccines* 2022; **7**.
422 doi:10.1038/s41541-022-00452-6

423 7 Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, *et al.* **Humoral**
424 **and Cellular Immune Response Elicited by mRNA Vaccination Against Severe**
425 **Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With**
426 **Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on**
427 **Current CD4 T-Lymphocyte Count.** *Clin Infect Dis* 2022; **75**:e552–e563.

428 8 Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, *et al.*
429 **Immunogenicity to COVID-19 mRNA vaccine third dose in people living with**
430 **HIV.** *Nat Commun* 2022; **13**:4922.

431 9 Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, *et al.* **Booster**
432 **Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People**
433 **With Human Immunodeficiency Virus.** *Clin Infect Dis* 2023; **76**:201–209.

- 434 10 Costiniuk CT, Singer J, Lee T, Langlois M-A, Arnold C, Galipeau Y, *et al.* **COVID-19**
435 **vaccine immunogenicity in people with HIV.** *AIDS* 2023; **37**:F1–F10.
- 436 11 Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, *et al.*
437 **Antibody response durability following three-dose coronavirus disease 2019**
438 **vaccination in people with HIV receiving suppressive antiretroviral therapy.** *AIDS*
439 2023; **37**:709–721.
- 440 12 Costiniuk CT, Singer J, Lee T, Galipeau Y, McCluskie PS, Arnold C, *et al.* **Antibody**
441 **neutralization capacity after coronavirus disease 2019 vaccination in people with**
442 **HIV in Canada.** *AIDS* 2023; **37**:F25–F35.
- 443 13 Kaida A, Brotto LA, Murray MCM, Côté HCF, Albert AY, Nicholson V, *et al.*
444 **Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-**
445 **Based Sample of Women and Gender Diverse Individuals in British Columbia,**
446 **Canada.** *AIDS Behav* 2022; **26**:2242–2255.
- 447 14 Liu Y, Han J, Li X, Chen D, Zhao X, Qiu Y, *et al.* **COVID-19 Vaccination in People**
448 **Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy,**
449 **Safety, and Immunogenicity.** *Vaccines* 2021; **9**:1458.
- 450 15 Wu S, Zhu S, Yan X, Xu Y, Xu H, Yang F, *et al.* **Willingness to receive the COVID-**
451 **19 vaccine among HIV positive men who have sex with men in China: a cross-**
452 **sectional study.** *BMC Public Health* 2023; **23**:64.
- 453 16 Yao Y, Chai R, Yang J, Zhang X, Huang X, Yu M, *et al.* **Reasons for COVID-19**
454 **Vaccine Hesitancy Among Chinese People Living With HIV/AIDS: Structural**
455 **Equation Modeling Analysis.** *JMIR Public Health Surveill* 2022; **8**:e33995.
- 456 17 Yek C, Gianella S, Plana M, Castro P, Scheffler K, Garcia F, *et al.* **Standard vaccines**
457 **increase HIV-1 transcription during antiretroviral therapy.** *AIDS* 2016; **30**:2289–
458 2298.
- 459 18 Negredo E, Domingo P, Sambeat MA, Rabella N, Vázquez G. **Effect of Pneumococcal**
460 **Vaccine on Plasma HIV-1 RNA of Stable Patients Undergoing Effective Highly**
461 **Active Antiretroviral Therapy.** *EJCMID* 2001; **20**:287–288.
- 462 19 Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S, *et al.* **Strong**
463 **serological responses and HIV RNA increase following AS03-adjuvanted**
464 **pandemic immunization in HIV-infected patients.** *HIV Medicine* 2012; **13**:207–218.
- 465 20 Günthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, *et al.* **Effect**
466 **of Influenza Vaccination on Viral Replication and Immune Response in Persons**
467 **Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral**
468 **Therapy.** *J Infect Dis* 2000; **181**:522–531.

- 469 21 Rey D, Krantz V, Partisani M, Schmitt M-P, Meyer P, Libbrecht E, *et al.* **Increasing**
470 **the number of hepatitis B vaccine injections augments anti-HBs response rate in**
471 **HIV-infected patients. Effects on HIV-1 viral load.** *Vaccine* 2000; **18**:1161–1165.
- 472 22 Kowalczyk A, Doener F, Zanzinger K, Noth J, Baumhof P, Fotin-Mleczek M, *et al.*
473 **Self-adjuvanted mRNA vaccines induce local innate immune responses that lead**
474 **to a potent and boostable adaptive immunity.** *Vaccine* 2016; **34**:3882–3893.
- 475 23 Iavarone C, O’Hagan DT, Yu D, Delahaye NF, Ulmer JB. **Mechanism of action of**
476 **mRNA-based vaccines.** *Expert Rev Vaccines* 2017; **16**:871–881.
- 477 24 Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, *et al.* **Safety and**
478 **immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-**
479 **CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.** *Lancet*
480 *HIV* 2021; **8**:474–485.
- 481 25 Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D, *et al.*
482 **Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-**
483 **1272.** *Int J Infect Dis* 2021; **113**:125–126.
- 484 26 Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, *et al.*
485 **Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people**
486 **living with HIV-1.** *Clin Microbiol Infect* 2021; **27**:1851–1855.
- 487 27 Matveev VA, Mihelic EZ, Benko E, Budyłowski P, Grocott S, Lee T, *et al.*
488 **Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older**
489 **people with HIV.** *iScience* 2023; **26**:107915.
- 490 28 Fusco FM, Carleo MA, Sangiovanni N, D’Abbraccio M, Tambaro O, Borrelli F, *et al.*
491 **Does COVID-19 Vaccination with BNT162b2 Influence HIV-Related**
492 **Immunological and Virological Markers? Data from 235 Persons Living with HIV**
493 **at Cotugno Hospital, Naples, Italy: Immune Response After Second and Third**
494 **Doses, and Influence on Immunovirological Markers.** *Viral Immunol* 2023; **36**:360–
495 365.
- 496 29 Tuttle DJ, Castanha PMS, Nasser A, Wilkins MS, Alaoui-El-Azher M, Cuff DE, *et al.*
497 **SARS-CoV-2 mRNA Vaccine Induced Immune Responses in Men with HIV-1 and**
498 **Impact on Proviral Reservoirs.** Published Online First: 16 April 2023.
499 doi:10.2139/ssrn.4417076
- 500 30 Portillo V, Fedeli C, Ustero Alonso P, Petignat I, Mereles Costa EC, Sulstarova A, *et al.*
501 **Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2**
502 **Vaccination in HIV-Infected Individuals.** *Front Immunol* 2022; **12**:820126.

- 503 31 Stevenson EM, Terry S, Copertino D, Leyre L, Danesh A, Weiler J, *et al.* **SARS CoV-2**
504 **mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells.** *Nat Commun*
505 2022; **13**:4888.
- 506 32 Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, *et al.* **A novel**
507 **quantitative approach for measuring the reservoir of latent HIV-1 proviruses.**
508 *Nature* 2019; **566**:120–125.
- 509 33 Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, *et al.* **HIV-1**
510 **diversity considerations in the application of the Intact Proviral DNA Assay**
511 **(IPDA).** *Nat Commun* 2021; **12**:165.
- 512 34 Public Health Agency of Canada. Canadian report on COVID-19 vaccine doses
513 administered. Ottawa: Public Health Agency of Canada; 2023. [https://health-](https://health-infobase.canada.ca/covid-19/vaccine-administration/)
514 [infobase.canada.ca/covid-19/vaccine-administration/](https://health-infobase.canada.ca/covid-19/vaccine-administration/) (accessed 20 Sep2023).
- 515 35 Public Health Agency of Canada. Canadian COVID-19 vaccination coverage report.
516 Ottawa: Public Health Agency of Canada; 2023. [https://health-](https://health-infobase.canada.ca/covid-19/vaccination-coverage/)
517 [infobase.canada.ca/covid-19/vaccination-coverage/](https://health-infobase.canada.ca/covid-19/vaccination-coverage/) (accessed 18 Sep2023).
- 518 36 Little N. COVID-19 Tracker Canada. 2020.COVID19Tracker.ca
- 519 37 Storey JD, Tibshirani R. **Statistical significance for genomewide studies.** *Proc Natl*
520 *Acad Sci U S A* 2003; **100**:9440–9445.
- 521 38 Public Health Agency of Canada. NACI rapid response: Extended dose intervals for
522 COVID-19 vaccines to optimize early vaccine rollout and population protection in
523 Canada. Public Health Agency of Canada; 2021. [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
524 [health/services/immunization/national-advisory-committee-on-immunization-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
525 [naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
526 [population-protection.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html) (accessed 7 Sep2023).
- 527 39 The Committee for Drug Evaluation and Therapy. Therapeutic Guidelines for
528 Antiretroviral (ARV) Treatment of Adult HIV Infection. British Columbia Centre for
529 Excellence in HIV/AIDS; 2023.
- 530 40 Panel on Antiretroviral Guidelines for Adults and Adolescents. HIV Clinical
531 Guidelines: Adult and Adolescent ARV - What's New in the Guidelines. Department of
532 Health and Human Services; 2023.
- 533 41 Nanditha NGA, Dong X, Tafessu HM, Wang L, Lu M, Barrios R, *et al.* **A province-**
534 **wide HIV initiative to accelerate initiation of treatment-as-prevention and**
535 **virologic suppression in British Columbia, Canada: a population-based cohort**
536 **study.** *CMAJ Open* 2022; **10**:E27–E34.

537

538 **Figure Legends:**

539

540 **Figure 1: Plasma HIV loads following one- and two-dose COVID-19 vaccination.** HIV
541 plasma viral loads prior to vaccination (left), one month after the first dose (middle), and
542 one month following the second dose (right). A black dashed line indicates the assay LLOQ
543 of 20 HIV copies/mL, while light grey dashed lines indicate clinically relevant pVL
544 thresholds of 50 and 200 HIV copies/mL. For graphing purposes, undetectable viral loads
545 were plotted as 10 HIV copies/mL, while viral loads that were detectable yet below the
546 LLOQ were plotted as 15 HIV copies/mL. As the vast majority of pVL measurements were
547 below the LLOQ, violin plots help visualize the data distribution. Each participant is
548 identified by a unique color that is consistent throughout all figures. P-values were
549 calculated using the Wilcoxon sum rank test for paired data.

550

551 **Figure 2: Measures of intact reservoir size, and total, 5'-defective, 3'-defective**
552 **proviral burdens after one- and two-dose COVID-19 vaccination.** Intact reservoir size
553 (*panel a*), total proviral burden (*panel b*), 5'-defective proviral burden (*panel c*), and 3'-
554 defective proviral burden (*panel d*) measured at baseline (pre-vaccine), one month after the
555 first vaccine dose, and one month after the second vaccine dose, using the Intact Proviral
556 DNA Assay (IPDA). Each participant is identified by a unique color that is consistent
557 throughout all figures. P-values were calculated using the Wilcoxon sum rank test for
558 paired data.

559

560 **Figure 3. Relationship between reservoir size, plasma viral load and COVID-19**
561 **vaccine immune response magnitude.** *Panel a:* Anti-SARS-CoV-2-Spike (S) serum
562 antibody levels one month following the first COVID-19 vaccine dose in participants with
563 pVL >20 HIV RNA copies/mL (top group) versus <20 HIV RNA copies/mL (bottom group)
564 at this time point. P-value calculated using the Mann-Whitney U-test. *Panel b:* same as *a*,
565 but for anti-S serum antibody levels and pVL one month after the second dose. *Panel c:*
566 Relationship between Anti-S serum antibody levels one month following the first COVID-
567 19 vaccine dose, and the fold-change in intact reservoir size from baseline, assessed using
568 Spearman's correlation. *Panel d:* same as *c*, but depicting the relationship between Anti-S
569 serum antibody levels one month following the second COVID-19 vaccine dose, and the
570 fold-change in intact reservoir size since the previous time point. Each participant is
571 identified by a unique color that is consistent throughout all figures.

572

573 **Figure 4. Population-level analysis of pVL test results in BC.** *Panel a:* The percentage
574 of all pVL tests performed in BC that returned a detectable result (defined as >40 HIV
575 RNA copies/mL; see methods) was computed for every month between 2012-2022 and
576 depicted as a smoothed mauve curve. The numbers underneath the x-axis denote the total
577 number of pVL tests performed each year. The smoothed blue line depicts the number of
578 COVID-19 vaccine doses administered in BC weekly, as retrieved from the COVID-19
579 Vaccine Tracker [36]. The shaded rectangle denotes the period when pVL load testing of
580 long-term ART-suppressed PWH was temporarily curtailed to preserve capacity for
581 COVID-19 diagnostic testing. *Panel b:* The percentage of PWH in BC receiving
582 uninterrupted ART who experienced at least one detectable pVL measurement (defined as


583 >40 HIV RNA copies/mL; see methods) for the given year. The total number of pVL tests
584 included in each year's analysis, as well as the total number of PWH from whom these pVL
585 data are derived, are shown on the x-axis.

Characteristic	N = 62
Age at enrolment in years, median (IQR)	43 (35, 56)
Sex at birth	
Male, n (%)	55 (89%)
Female, n (%)	7 (11%)
Nadir CD4+ T-cell count in cells/mm ³ , median (IQR)	305 (160, 498)
Baseline ^a CD4+ T-cell count in cells/mm ³ , median (IQR)	725 (475, 915)
Baseline ^a plasma viral load in copies HIV RNA/mL, median (IQR)	<20 (<20, <20)
Years on ART, median (IQR)	6 (3, 14)
Current ART regimen	
INSTI-based, n (%)	46 (74%)
NNRTI-based, n (%)	6 (9.7%)
PI-based, n (%)	5 (8.1%)
Intensive ^a , n (%)	4 (6.5%)
CCR5 antagonist-based, n (%)	1 (1.6%)
Initial COVID-19 vaccine regimen	
BNT162b2 + BNT162b2, n (%)	43 (69%)
mRNA-1273 + mRNA-1273, n (%)	16 (26%)
BNT162b2 + mRNA-1273, n (%)	3 (4.8%)
COVID-19 exposure history	
COVID-19 naive throughout follow-up, n (%)	57 (92%)
COVID-19-experienced prior to vaccination, n (%)	4 (6.5%)
COVID-19 between first and second vaccine doses, n (%)	1 (1.6%)


^a At study entry (*i.e.* prior to COVID-19 vaccination)

^b Regimen containing at least two of the following drug classes: INSTI, NNRTI, PI, CCR5 antagonist


Figure 1




(a) Figure 2




(b)




(c)




(d)




(a) Figure 3



(b)



(c)



(d)




Figure 4

